STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #955 by analyst upside · 2026-06-27
DYN
Dyne Therapeutics, Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+82.7%
implied upside to consensus target
Current Price $20.94
Consensus Target $38.25
Bull Target $50.0
Bear Target $17.0
Analysts Covering 16
ANALYST CONSENSUS — BUY
Strong Buy
3
Buy
11
Hold
2
Sell
0
52-Week Low $8.06
52-Week High $25.0
YTD Return +13.2%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E -7.0x
EPS (TTM) $-3.15
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.06
52-Week High $25.0
Current Price $20.94
Bear Target $17.0
Bull Target $50.0
● Now $20.94 ● Target $38.25
TRADING DATA
Avg Volume 1.7M
YTD Return +13.2%
Analyst Count 16
Consensus Buy
Upside to Target +82.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Dyne Therapeutics, Inc. (DYN) is currently trading at $20.94 with a Wall Street consensus price target of $38.25, implying potential upside of 82.7% over the next 12 months. 16 analysts currently cover DYN, with a consensus rating of Buy — 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $50.0, while the most cautious has a target of $17.0.

DYN operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 13.2% year-to-date and is currently trading near the upper end of its 52-week range of $8.06 – $25.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for DYN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Evercore ISI Group — Reiterated
Outperform → Outperform 2026-05-15 Building track record
Bernstein — Reiterated
Market Perform → Market Perform 2026-05-13 Building track record
Chardan Capital — Reiterated
Buy → Buy 2026-03-09 33% win rate (6 calls)
Morgan Stanley — Reiterated
Overweight → Overweight 2026-03-03 Building track record
Chardan Capital — Reiterated
Buy → Buy 2026-03-03 33% win rate (6 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-03 31% win rate (48 calls)
JP Morgan — Reiterated
Neutral → Neutral 2026-01-20 43% win rate (7 calls)
Evercore ISI Group — Reiterated
Outperform → Outperform 2025-12-15 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →